1h Free Analyst Time
The Global Acute Myeloid Leukemia Therapeutics Market size was estimated at USD 757.74 million in 2022, USD 856.20 million in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.47% to reach USD 2,083.11 million by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Acute Myeloid Leukemia Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
Market Segmentation & Coverage:
This research report categorizes the Global Acute Myeloid Leukemia Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:- Based on Disease Type, the market is studied across Myeloblastic, Myelomonocytic, and Promyelocytic. The Myelomonocytic is projected to witness significant market share during forecast period.
- Based on Treatment Type, the market is studied across Chemotherapy and Targeted Therapy. The Chemotherapy is projected to witness significant market share during forecast period.
- Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Retail Pharmacy is projected to witness significant market share during forecast period.
- Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Global Acute Myeloid Leukemia Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.The report provides insights on the following pointers:
- Market Penetration: Provides comprehensive information on the market offered by the key players
- Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
- Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
- Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
- Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
- What is the market size and forecast of the Global Acute Myeloid Leukemia Therapeutics Market?
- What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Myeloid Leukemia Therapeutics Market during the forecast period?
- Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Myeloid Leukemia Therapeutics Market?
- What is the competitive strategic window for opportunities in the Global Acute Myeloid Leukemia Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Global Acute Myeloid Leukemia Therapeutics Market?
- What is the market share of the leading vendors in the Global Acute Myeloid Leukemia Therapeutics Market?
- What modes and strategic moves are considered suitable for entering the Global Acute Myeloid Leukemia Therapeutics Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Acute Myeloid Leukemia Therapeutics Market, by Disease Type
7. Acute Myeloid Leukemia Therapeutics Market, by Treatment Type
8. Acute Myeloid Leukemia Therapeutics Market, by Distribution Channel
9. Americas Acute Myeloid Leukemia Therapeutics Market
10. Asia-Pacific Acute Myeloid Leukemia Therapeutics Market
11. Europe, Middle East & Africa Acute Myeloid Leukemia Therapeutics Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix
List of Figures
List of Tables
Companies Mentioned
- AbbVie Inc.
- Actinium Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Astex Pharmaceuticals, Inc.
- CTI BioPharma Corp.
- Cyclacel Pharmaceuticals, Inc.
- Daiichi Sankyo Company, Limited
- Eisai Co., Ltd.
- F. Hoffmann-La Roche AG
- Jazz Pharmaceuticals PLC
- Johnson & Johnson Services, Inc.
- MEI Pharma, Inc.
- Merus N.V.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- The Bristol Myers Squibb Company
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 187 |
| Published | March 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 856.2 Million |
| Forecasted Market Value ( USD | $ 2083.11 Million |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
